A hepatitis B virus causes chronic infections in equids worldwide

Autor: Rasche A., Lehmann F., Goldmann N., Nagel M., Moreira-Soto A., Nobach D., de Oliveira Carneiro I., Osterrieder N., Greenwood A. D., Steinmann E., Lukashev A. N., Schuler G., Glebe D., Drexler J. F., Aguilar-Setien A., Azab W., Carluccio A., Dietrich D., Franke C. R., Garcia-Bocanegra I., Garcia-Lacy F., Jeworoski L. M., Jores J., Kepper R., Netto E. M., Owusu-Dabo E., Ribas J. R. L., Roncoroni C., Roppert P. L., Rusenov A., Rusenova N., Sandev N., Seeber P. A., Shnaiderman-Torban A., Steinman A., Tegtmeyer B., Veneziano V., Veronesi M. C., Walter S., Zapryanova D.

Publikováno v: Proc Natl Acad Sci U S A
Proceedings of the National Academy of Sciences of the United States of America, 118(13):e2013982118

Preclinical testing of novel therapeutics for chronic hepatitis B (CHB) requires suitable animal models. Equids host homologs of hepatitis C virus (HCV). Because coinfections of hepatitis B virus (HBV) and HCV occur in humans, we screened 2,917 speci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c51effa0cbaeab7b17418bda6a6d535b
https://doi.org/10.1073/pnas.2013982118